Skip to main content
Equibles
CLDI logo

CLDI · Calidi Biotherapeutics, Inc. · Metrics

Track CLDI — free

Use CLDI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CLDI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.70 -0.07 (-8.74%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company estimates that based on the Company's liquidity resources, there is substantial doubt about the Company's ability to continue as a going concern within 12 months from the date of issuance of these unaudited condensed consolidated financial statements.”
View the 10-Q filed Aug 13, 2026
Market Cap
$1.98M
Shares
2.58M
Volume · Oct 22 112.04K Avg daily vol (58 sessions) 150.32K

CLDI metrics

50 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.77
Market cap
$1.98M

Price action

20 metrics
Price change (1W)
-12.1%
Price change (30D)
-30.8%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Beta
—
RSI (14D)
21.5
Price vs SMA 50
-34.9%
Price vs SMA 200
—
Avg volume (3M)
150,322
Relative volume
0.4
Average dollar volume
$195,134

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
2.58M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.6
reciprocal yield 157.9%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-876.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2024-09-11

Profitability

9 metrics
Gross margin
—
Operating margin
-51,395.6%
Trailing 12 months
Net margin
-56,504.4%
Gross profit (TTM)
—
Operating profit (TTM)
−$17.85M
Net income (TTM)
−$17.40M
Trailing 12 months
Diluted EPS (TTM)
$-37.91
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$8.33

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+686.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-555.3%
Return on assets
-241.5%
Debt / equity
0.2
Current ratio
1.7
EBITDA (TTM)
−$16.14M
Free cash flow (TTM)
—
Quick ratio
1.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$3.69M
Latest balance sheet
Cash & equivalents
$4.29M
Total assets
$7.20M
Total debt
$600,000

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$17.75M
Capital expenditures (TTM)
—
R&D (TTM)
$9.86M
SG&A (TTM)
$7.99M
Stock compensation (TTM)
$1.37M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
23
13F filer change QoQ
-5
Institutional ownership
1.3%
Conviction holders (share of 13F filers)
4.3%
Crowding (high-turnover and private-fund holders)
0.9%
Private-fund adviser ownership
0.6%
Active holders' share change QoQ
-81.2%
Holder tenure
4.7
Price vs estimated holder cost
-96.8%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.2%

Short interest

3 metrics
Short interest
9.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
49 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1855485 CUSIP 320703507 13F (30d) 1 filings 1 filers Visit website Investor relations